Guardian Pharmacy Services (NYSE:GRDN) Price Target Raised to $43.00

Guardian Pharmacy Services (NYSE:GRDN) had its price objective hoisted by investment analysts at Truist Financial from $38.00 to $43.00 in a research note issued on Monday,Benzinga reports. The firm currently has a “buy” rating on the stock. Truist Financial’s target price would indicate a potential upside of 9.18% from the company’s current price.

A number of other brokerages have also recently issued reports on GRDN. Zacks Research raised shares of Guardian Pharmacy Services from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, March 18th. UBS Group reaffirmed a “buy” rating on shares of Guardian Pharmacy Services in a research note on Thursday, March 12th. Wall Street Zen cut shares of Guardian Pharmacy Services from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Oppenheimer upped their price objective on shares of Guardian Pharmacy Services from $35.00 to $38.00 and gave the company an “outperform” rating in a research note on Thursday, March 12th. Finally, Raymond James Financial reaffirmed an “outperform” rating and issued a $40.00 price objective on shares of Guardian Pharmacy Services in a research note on Thursday, March 12th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, Guardian Pharmacy Services currently has an average rating of “Buy” and an average price target of $40.20.

Guardian Pharmacy Services Trading Up 0.6%

Shares of NYSE:GRDN traded up $0.24 during trading on Monday, reaching $39.39. The company had a trading volume of 56,346 shares, compared to its average volume of 380,342. The company has a fifty day moving average of $34.65 and a two-hundred day moving average of $30.76. The stock has a market capitalization of $2.49 billion, a P/E ratio of 51.14 and a beta of 0.47. Guardian Pharmacy Services has a 12 month low of $19.17 and a 12 month high of $41.36.

Guardian Pharmacy Services (NYSE:GRDN) last issued its quarterly earnings results on Wednesday, March 11th. The company reported $0.37 EPS for the quarter, topping analysts’ consensus estimates of $0.27 by $0.10. The firm had revenue of $397.62 million for the quarter, compared to analyst estimates of $390.04 million. Guardian Pharmacy Services had a net margin of 3.40% and a return on equity of 31.64%. The company’s revenue was up 17.4% compared to the same quarter last year. As a group, equities research analysts predict that Guardian Pharmacy Services will post 0.87 earnings per share for the current year.

Insider Buying and Selling at Guardian Pharmacy Services

In other Guardian Pharmacy Services news, insider Fred Burke sold 671,432 shares of the stock in a transaction on Friday, March 20th. The shares were sold at an average price of $29.68, for a total transaction of $19,928,101.76. Following the completion of the sale, the insider owned 840,413 shares of the company’s stock, valued at $24,943,457.84. This represents a 44.41% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, major shareholder Equity Fund L.P. Cardinal sold 275,728 shares of the stock in a transaction on Friday, March 20th. The shares were sold at an average price of $29.68, for a total transaction of $8,183,607.04. Following the sale, the insider directly owned 345,123 shares of the company’s stock, valued at $10,243,250.64. The trade was a 44.41% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 9,726,405 shares of company stock worth $288,679,700 over the last ninety days. 32.96% of the stock is owned by company insiders.

Institutional Investors Weigh In On Guardian Pharmacy Services

Institutional investors have recently added to or reduced their stakes in the company. Rakuten Investment Management Inc. purchased a new stake in Guardian Pharmacy Services during the 3rd quarter valued at $433,000. CSM Advisors LLC boosted its position in Guardian Pharmacy Services by 40.9% during the 3rd quarter. CSM Advisors LLC now owns 135,665 shares of the company’s stock valued at $3,559,000 after buying an additional 39,360 shares during the period. Aristotle Capital Boston LLC boosted its position in Guardian Pharmacy Services by 58.5% during the 3rd quarter. Aristotle Capital Boston LLC now owns 649,463 shares of the company’s stock valued at $17,035,000 after buying an additional 239,790 shares during the period. TimesSquare Capital Management LLC boosted its position in Guardian Pharmacy Services by 5.6% during the 3rd quarter. TimesSquare Capital Management LLC now owns 860,173 shares of the company’s stock valued at $22,562,000 after buying an additional 45,950 shares during the period. Finally, Peregrine Capital Management LLC boosted its position in Guardian Pharmacy Services by 8.2% during the 3rd quarter. Peregrine Capital Management LLC now owns 232,011 shares of the company’s stock valued at $6,086,000 after buying an additional 17,632 shares during the period.

Guardian Pharmacy Services Company Profile

Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company’s Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs.